Lifeward Ltd.
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
LFWD · Price history
Price at last available close
$6.04
−$0.88 (-12.72%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Lifeward Ltd.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with spinal cord injuries (SCI), granting them the ability to stand, walk, pivot, and navigate staircases by providing assistive hip and knee motion. Key offerings from the company include the ReWalk Exo-Suit and the ReWalk Personal 6.
How they make money
Lifeward generates revenue primarily through the sale and lease of medical devices, including exoskeleton systems and anti-gravity systems, as well as through the provision of related services, maintenance, and training. The company sells its products directly to healthcare facilities and individual users, and through third-party distributors, while also seeking reimbursement from public and private health insurance providers.
Products & services
The company offers mobility and rehabilitation solutions, including the ReWalk Personal and Rehabilitation Exoskeletons for individuals with spinal cord injuries, and AlterG Anti-Gravity systems which use differential air pressure technology for physical therapy and athletic training.
Brands & revenue mix
Exoskeleton systems for individuals with spinal cord injuries.
Separate brand revenue is not available in this research.Source
Anti-Gravity systems for physical therapy and athletic training.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Customer concentration
The company discloses that it is subject to risks related to customer concentration, noting that a significant portion of its revenue is derived from a limited number of customers and distributors, as detailed in the 2025 annual report.
Suppliers, materials & equipment
- Contract Manufacturers — The company relies on third-party contract manufacturers for the production of its exoskeleton and anti-gravity systems; specific supplier names are not disclosed.Source
Competitors
Strengths
Company-specific research
Questions worth answering for LFWD
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving LFWD's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can LFWD fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does LFWD's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for LFWD to reach sustainable profitability?
- •What future growth or profitability would be needed to justify LFWD's current valuation?
Essential Investment Snapshot
Market Cap
$9.7M
P/E Ratio
-0.4
EPS
$-16.82
52-Week High
$10.20
52-Week Low
$4.14
Beta
0.40
Analyst Target
$10.00
Shares Outstanding
1.6M
Total Debt
$11.1M
Dividend
No current dividend
Liquidation Value / Share
$7.58
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
High movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for LFWD
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-57.3x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on LFWD.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +FDA clearance for ReWalk 7 Personal Exoskeleton.
- +Diversified product portfolio including AlterG systems.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Devices industry.
- −Dependence on third-party reimbursement and insurance coverage.
- −History of operating losses and potential need for additional capital.
- −Diluted weighted-average shares increased 199.0% year over year.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$6.04
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.8M | $22.0M | $25.7M | $13.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $14.0M | $13.6M | $17.4M | $9.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $7.8M | $8.4M | $8.2M | $4.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $9.2M | $3.2M | $4.6M | $4.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $21.4M | $22.1M | $23.1M | $23.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $30.6M | $25.3M | $27.8M | $28.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$24.4M | -$19.3M | -$24.9M | -$20.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$22.7M | -$16.9M | -$19.6M | -$23.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $1.3M | $295K | $128K | $20K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$30.9M | -$20.0M | -$28.9M | -$22.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$50K | -$55K | $43K | -$12K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$30.8M | -$19.9M | -$28.9M | -$22.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-16.82 | $-17.16 | $-39.96 | $-31.08 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 2.80M | 11.61M | 724K | 711K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 2.80M | 11.61M | 724K | 711K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$6.6M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$4.12
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+2852.3%
Cash Change
+83.8%
Margin Change
-59.3 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Margins contracted
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, cash levels. Pressure indicators included EPS growth, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 15.7%. EPS declined 40.8%. Cash increased 83.8%. Total debt increased 2852.3%. Net income margin declined by 59.3 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DevicesNews
Lifeward's ReWalk® Personal Exoskeleton Demonstrates Sustained Long-Term Home Use and Patient Satisfaction in Latest Independent Peer-Reviewed Study
Peer-Reviewed Study of Lifeward's ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain
Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer
Rumor Mill · LFWD
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial